AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03210220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pecs II block
Description: After identifying the axillary vein and artery, the ultrasound probe was positioned inferio-laterally, between the 3rd and 4th ribs, and then the pectoralis major and minor, and serratus anterior muscles were confirmed. The needle was advanced in a medio-lateral direction in-plane view of the ultrasound. For the Pecs II block, a total 30 mL of 0.5% ropivacaine was injected. First, the needle tip was advanced into the fascia between the pectoralis major and minor muscles and 10 mL of 0.5% ropivacaine was injected. Thereafter, the needle tip was advanced into the tissue plane between the pectoralis minor and serratus anterior muscles, and 20 mL of 0.5% ropivacaine was injected in a similar manner.
Study NCT03098524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (LTV arm)
Description: During cardiopulmonary bypass, mechanical ventilation is maintained with settings described above.
Study NCT03098524 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No ventilation (noV arm)
Description: During cardiopulmonary bypass, no mechanical ventilation is performed.
Study NCT03098524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung recruitment manoeuver
Description: An insufflation with positive end-expiratory pressure +30 cmH20 during 5 seconds.~At the end of cardiopulmonary bypass, in the operative room. And after transfer to the ICU (intensive care unit).
Study NCT03098524 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lung recruitment manoeuver
Description: An insufflation with positive end-expiratory pressure +30 cmH20 during 5 seconds.~At the end of cardiopulmonary bypass, in the operative room. And after transfer to the ICU (intensive care unit).
Study NCT03128489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Subjects will receive (Infanrix-IPV/Hib) as three-dose primary vaccination course at 6, 10 and 14 weeks of age. The vaccine will be administered intramuscularly, at a 90-degree angle into the anterolateral side of the thigh on the right side. The vaccine should not be administered in the buttock.
Study NCT01255306 — intervention group
Intervention type: OTHER
Intervention: Optical coherence tomography
Description: Optical coherence tomography will be performed in all study patients following pars plans vitrectomy and silicone oil tamponade. A fellow eye of each patient will serve as a control. Each patient enrolled in a study will receive 4 measurements:~1. On 7th postoperative day~2. On 30th postoperative day~3. On 90th postoperative day~4. On 180th postoperative day
Study NCT01255306 — intervention group
Intervention type: DRUG
Intervention: Local medical treatment of raised intraocular pressure
Description: In patients with raised intraocular pressure following medications will be employed in order to control the intraocular pressure:~Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution; b.i.d.) Ganfort (Bimatoprost, timolol maleate ophthalmic solution; once daily) Alphagan (Brimonidine ophthalmic solution; b.i.d.) In patients with intraocular pressure less than 27 mmHg Alphagan will be prescribed. In patients with intraocular pressure greater than 27 mmHg either Cosopt, or Ganfort will be prescribed under the discretion of treating physician. If intraocular pressure in patients treated with either Cosopt or Ganfort does not drop under 21 mmHg, Alphagan will be added.
Study NCT00529698 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biologically active recombinant Tat protein
Study NCT01511510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: PF-04958242 0.05 mg oral solution Q24 hours for 14 days
Study NCT01511510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: PF-04958242 0.10 mg oral solution Q24 hours for 14 days
Study NCT01511510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: PF-04958242 0.15 mg oral solution Q24 hours for 14 days
Study NCT01511510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: PF-04958242 0.25 mg oral solution Q24 hours for 14 days
Study NCT01511510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution Q24 hours for 14 days
Study NCT03792165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action observation therapy
Description: The normal human movement will be recorded and than the patients will be watched them.
Study NCT03792165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Strengthening and stretching exercise programme focuses on hip and knee muscles
Study NCT03792165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Strengthening and stretching exercise programme focuses on hip and knee muscles
Study NCT02521389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PWT-143
Description: phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) delta inhibitor
Study NCT04605939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Each subject undergoes PET/MR imaging within 40-60 minutes after injection.
Study NCT04605939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Each subject undergoes PET/CT imaging within 40-60 minutes after injection.
Study NCT03297333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: The resistance training group
Study NCT03297333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic interval training
Description: The aerobic interval training group
Study NCT04748692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local exercise therapy
Description: The local exercise therapy group will focus on strengthening knee and hip muscles three times a week for 6 weeks. Once a week, patients will train with the support of a physiotherapist. The physiotherapist gradually increases the intensity of the exercises improving muscle endurance. The exercises will be supplemented with mobilisations of the patellofemoral joint. Twice a week, patients train at home following a prescribed exercise program writing down their work-out in an exercise journal.
Study NCT04748692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal manual therapy
Description: The spinal manual therapy group will be treated one a week for 6 weeks. Before the first intervention an experienced manual therapist performed a clinical examination of the lower back, SIJ, hip and knee. Anatomical maps showing innervation areas of spinal nerve roots will be used to explain the regional interdependence model in the treatment of anterior knee pain. Manual therapy treatment will include manipulations of the thoracolumbar (T12-L3) region or SIJ as well as hip joint. Manipulation will be conducted if a restriction of range of motion will be found in any of the regions. Patients will also be asked to do home exercises focusing on mobilizing the thoracolumbar region and to write down their performance in an exercise journal.
Study NCT01760187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomitapide
Study NCT03685058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light curable resin modified glass ionomer varnish
Description: Treatment of non-cavitated proximal carious lesions with light curable resin modified glass ionomer varnish at initial and six-months follow-up visits, in addition, the patient will receive standard-of-care preventive measures, at initial, six-months follow-up, and 12-months follow-up visits.
Study NCT03685058 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard-of-care preventive measures
Description: Patient will receive standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish, oral hygiene instructions, and dietary counseling at initial, six-months follow-up, and 12-months follow-up visits
Study NCT03685058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard-of-care preventive measures
Description: Patient will receive standard-of-care preventive measures which include application of 5% sodium fluoride topical varnish, oral hygiene instructions, and dietary counseling at initial, six-months follow-up, and 12-months follow-up visits
Study NCT03678051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: Standard of care residential treatment
Study NCT03678051 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Standard of care residential treatment
Study NCT00085917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double dose pegylated interferon with weight based Ribavirin
Description: pegylated interferon alfa -2a 180ug/twice weekly and weight based ribavirin for 4 weeks then pegylated interferon alfa -2a 180ug/ weekly for the remainder of the treatment
Study NCT00085917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard dose pegylated interferon alfa -2a and ribavirin
Description: pegylated interferon alfa -2a 180ug weekly and weight based ribavirin for duration of the treatment
Study NCT01206790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NET
Description: Narrative Exposure Therapy for traumatized survivors of organized violence
Study NCT04197141 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventionally-fractionated WPRT
Description: Total dose: 45 Gy in 25 fractions WPRT
Study NCT04197141 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated WPRT
Description: Total dose: 25 Gy in 5 fractions WPRT
Study NCT00211874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-management
Description: bilingual nurses counseled patients on diet, medication adherence, and self-management of symptoms through an initial visit and regularly scheduled follow-up telephone calls and facilitated evidence-based changes to medications in discussions with patients' clinicians.
Study NCT03347812 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular Aortic Repair
Description: Without surgery to expose the lesion directly, minimal invasive treatment for the aortic arch lesion under the guidance of imaging equipment is performed through the blood vessel with a tiny wound of a few centimeters, in our research, including chimney, branch stent-grafts and fenestration techniques.
Study NCT03347812 — intervention group
Intervention type: PROCEDURE
Intervention: Total Arch Replacement
Description: A kind of open surgery is performed for the replacement of total aortic arch.
Study NCT01597011 — intervention group
Intervention type: PROCEDURE
Intervention: Fibrin Sealant
Description: Use of fibrin sealant for mesh fixation in laparoscopic inguinal hernia repair,
Study NCT01597011 — intervention group
Intervention type: PROCEDURE
Intervention: Tissue-penetrating mesh-fixation
Description: Use of tacks, staples or sutures for mesh fixation in inguinal hernia repair
Study NCT02037451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rhythmic auditory stimulation
Description: Participants perform the finger tapping at the same time give rhythmic auditory stimulation ,and need to execute tapping with auditory stimulation.
Study NCT01948869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phoenix II (BAY81-2996)
Study NCT01948869 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phoenix I (BAY81-2996)
Study NCT01385267 — intervention group
Intervention type: PROCEDURE
Intervention: aspiration of amniotic fluid
Description: a sample of amniotic fluid will be drawn from the amniotic sac of Twin A and Twin B. Each amniotic sac will be aspirated by the obstetrician and sent to the laboratory for determination of fetal lung maturity index and lamellar body count.
Study NCT00603733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ASA (5-Aminosalicylate)
Description: 500 mg tablet (modified extended release)
Study NCT00603733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-ASA (5-Aminosalicylate)
Description: 500 mg tablet
Study NCT04712357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C 500 MG Oral Tablet
Description: Vitamin C 500 MG per day for 10 days
Study NCT04712357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxyl fumarate 300 MG Oral Tablet
Description: Tenofovir disoproxyl fumarate 300 MG per day for 10 days
Study NCT04712357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG Oral Tablet
Description: Tenofovir disoproxyl fumarate 300 MG plus emtricitabine 200 MG per day for 10 days
Study NCT02062398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Reprieve System
Description: BlueWind Medical neurostimulator for the treatment of neuropathic pain
Study NCT03411668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EBP Educational Programme
Description: The educational EBP programme will include 12 hours of classroom lessons regarding EBP more 6 hours of mentorship made to a small groups of students (2 or 3 students per group).
Study NCT00961870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm vibration
Description: Mechanical loading with forearm vibration will be applied right radius in all groups.
Study NCT04208646 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal progenitor cells
Description: Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra- articular use
Study NCT04208646 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: No mesenchymal progenitor cells
Description: No mesenchymal progenitor cells for intra- articular use
Study NCT00947843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin + pregrel (Clopidogrel resinate)
Study NCT00947843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aspirin + placebo
Study NCT00947843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin + plavix (Clopidogrel bisulfate)
Study NCT04416945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Household Reactive Case Detection
Description: Within 7 days of the index case notification, all members of the index case's household and everyone in the neighboring five households will then be invited to participate in the study. After consenting, a finger stick blood sample will be collected for each consenting individual for testing with the HS-RDT for P. falciparum, a standard combination RDT, and four blood spots on filter paper.
Study NCT04416945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RACD of cases' co-workers/co-travelers
Description: Index cases will be screened by the VMW at their households at the time of case investigation to determine if they have traveled or worked in a forest or forest-fringe area within the past 30 days. If eligible, the case will trigger two reactive recruitment strategies to screen and treat others who recently traveled or worked with the case in a forest or forest-fringe location:~1. Peer-referral RACD (PR-RACD): In this strategy, the case will identify specific co-travelers or co-workers resident in their village who had spent the night with the case at a forest or forest-fringe area and spent the night there in the past 30 days.~2. Venue-based RACD (VB-RACD): In this strategy, co-workers will be recruited directly from (accessible) forest or forest-fringe work sites where the index case worked and spent at least one night in the past 30 days.
Study NCT04416945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Case Management and Follow-up
Description: All individuals who test positive by either HS-RDT or Standard RDT will be told of their results and treated on site per national guidelines:~* Individuals with P. falciparum infection will be treated with an age-appropriate course of artemether-lumefantrine (AL) and a single low dose of primaquine (SLD-PQ). Weight-based dosing is described in Tables 2 and 3 below.~* At all study sites in Lao Peoples Democratic Republic, patients with a P. vivax infection identified by RDT (both febrile and asymptomatic) will be given a unique coded and signed informational letter directing them to the nearest district hospital (or other testing facility) for G6PD deficiency testing and possible radical cure administration depending on results. At the health facility, G6PD normal individuals will be treated with AL and a 14-day course of PQ, whereas G6PD deficient individuals will receive AL alone as per the national guidelines and referred to a hospital for further primaquine management decisions.
Study NCT04416945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case Management and Follow-up
Description: All individuals who test positive by either HS-RDT or Standard RDT will be told of their results and treated on site per national guidelines:~* Individuals with P. falciparum infection will be treated with an age-appropriate course of artemether-lumefantrine (AL) and a single low dose of primaquine (SLD-PQ). Weight-based dosing is described in Tables 2 and 3 below.~* At all study sites in Lao Peoples Democratic Republic, patients with a P. vivax infection identified by RDT (both febrile and asymptomatic) will be given a unique coded and signed informational letter directing them to the nearest district hospital (or other testing facility) for G6PD deficiency testing and possible radical cure administration depending on results. At the health facility, G6PD normal individuals will be treated with AL and a 14-day course of PQ, whereas G6PD deficient individuals will receive AL alone as per the national guidelines and referred to a hospital for further primaquine management decisions.
Study NCT00583661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EXCOR Pediatric
Description: Extracorporeal Ventricular Assist Device
Study NCT01817114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auto Remote Ischemic Conditioning (AutoRIC) device
Study NCT01817114 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Auto Remote Ischemic Conditioning (AutoRIC) device
Study NCT01744457 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Measurement of tear film osmolarity with the TearLab® instrument
Study NCT01744457 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Schirmer I test
Study NCT01744457 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tear break up time
Study NCT01744457 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optical Quality Analysis System
Description: Measurement of the objective scattering index (OSI)
Study NCT01744457 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ocular Surface Disease Index
Study NCT01893684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: PRO+EX and CARB+EX groups will be prescribed an exercise program with required attendance of 3 nonconsecutive days per week. Exercise sessions will be supervised and conducted by trained graduate students in the Department of Kinesiology. Based on recommended practice, a program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last \~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, \~30 min of resistance training, and finally, a \~10 min of balance and flexibility exercises during the cool-down period. Endurance training activities will vary but will all be weight-bearing.
Study NCT01893684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Higher Protein Diet
Description: PRO diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; \~30% of energy intake) with a ratio of carbohydrate/protein of \<1.5 and dietary lipids at \~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by \~500 kcal/d. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or \~100 grams. This amount of lean cooked beef provides an average of \~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). Our dietary prescription to the PRO groups that they add 3 ounces (and perhaps up to 3.5 ounces pending body size) of lean beef daily will provide an additional 25-30 grams of protein. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit.
Study NCT01893684 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Carbohydrate Diet
Description: For the CARB group, the diet will provide dietary protein at 0.8 g.kg-1.d-1 (\~ 18% of energy intake) with a ratio of carbohydrates/protein > 3.5 and dietary lipids at \~ 30% energy intake. Through nutrition education and counseling we will ensure that the CARB group meets the RDA for protein for women of 46 grams per day from a variety of plant and animal sources. Again, energy deficit will be determined by reducing estimated daily energy needs by \~500 kcal/d. Additional recommendations will include 5 servings/day of vegetables and 2-3 servings/day of fruit. Beef intake will be discouraged in the CARB group.
Study NCT00587015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAT-8015
Description: The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60...μg/kg until toxicity supervenes.